Clinical Trial Update: Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating refametinib in combination with regorafenib in advanced/metastatic cancer was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Refametinib (refametinib)
• Regorafenib (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2018-01-26